Lp-PLA2 and sPLA2: cardiovascular biomarkers

被引：10
|
作者：
Ait-Oufella, Hafid [1 ,2 ]
Mallat, Ziad [1 ,3 ]
Tedgui, Alain [1 ]
机构：
[1] Univ Paris 05, Paris Ctr Rech Cardiovasc PARCC, INSERM, U970, F-75015 Paris, France
[2] Hop St Antoine, AP HP, Serv Reanimat Med, F-75571 Paris, France
[3] Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England
来源：
M S-MEDECINE SCIENCES | 2014年 / 30卷 / 05期
关键词：
SECRETORY PHOSPHOLIPASE A(2); CORONARY-ARTERY-DISEASE; C-REACTIVE PROTEIN; ISCHEMIC-STROKE; PROGNOSTIC UTILITY; HEALTHY-MEN; RISK; EVENTS; ATHEROSCLEROSIS; ASSOCIATION;
D O I：
10.1051/medsci/20143005015
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Phospholipases A2 (PLA2) belong to a superfamily of enzymes that catalyze the hydrolysis of glycerophospholipids at the sn-2 position, producing nonesterified fatty acids and lysophospholipids. Many experimental studies have shown that PLA2 are involved in lipid metabolism and immuno-inflammatory response and participate in the development of atherosclerosis. In humans, therapeutic approaches based on the inhibition of PLA2 are currently in development. This review summarizes human studies regarding the prognostic value of two members of the family of PLA2, Lp-PLA2 (lipoprotein-associated PLA2) and sPLA2 (secretory PLA2), in cardiovascular diseases.
引用
收藏
页码：526 / 531
页数：6
相关论文
共 50 条
  • [1] The effect of intensive insulin treatment on plasma level of LP-PLA2 and sPLA2 in patients with newly diagnosed type 2 diabetes
    Lin, X-H.
    Xu, M.
    Li, F.
    Mai, L.
    Wang, X.
    Li, Y.
    Yan, L.
    DIABETOLOGIA, 2013, 56 : S469 - S469
  • [2] Lp-PLA2 as a Marker of Cardiovascular Diseases
    Sabha Bhatti
    Abdul Hakeem
    Mehmet Cilingiroglu
    Current Atherosclerosis Reports, 2010, 12 : 140 - 144
  • [3] Lp-PLA2 as a Marker of Cardiovascular Diseases
    Bhatti, Sabha
    Hakeem, Abdul
    Cilingiroglu, Mehmet
    CURRENT ATHEROSCLEROSIS REPORTS, 2010, 12 (02) : 140 - 144
  • [4] The Effect of Intensive Insulin Treatment on Plasma Level of LP-PLA2 and sPLA2 in Patients With Newly Diagnosed T2DM
    Lin, Xiu-Hong
    Xu, Mingtong
    Li, Feng
    Wang, Xiaoyun
    Mai, Lifang
    Li, Yan
    Yan, Li
    DIABETES, 2013, 62 : A253 - A253
  • [5] 颈动脉狭窄患者术前外周血Lp-PLA2和sPLA2水平变化及其临床意义
    刘晓佳
    伍健明
    张猛
    何毅
    张协军
    深圳中西医结合杂志, 2016, 26 (21) : 1 - 3+199
  • [6] Genetic Association Between Variants in Genes for sPLA2 and Cardiovascular Biomarkers
    Ding, Bo
    Hurt-Camejo, Eva
    Chu, Audrey Y.
    Chasman, Daniel I.
    Ridker, Paul M.
    Nyberg, Fredrik
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 322 - 322
  • [7] Lp-PLA2 Inhibitors for the Reduction of Cardiovascular Events
    Steen D.L.
    O'Donoghue M.L.
    Cardiology and Therapy, 2013, 2 (2) : 125 - 134
  • [8] Deciphering the Causal Role of sPLA2s and Lp-PLA2 in Coronary Heart Disease
    Talmud, Philippa J.
    Holmes, Michael V.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2015, 35 (11) : 2281 - 2289
  • [9] Modeling the cardiovascular burden associated with elevated Lp-PLA2
    Koro, C. E.
    Davies, R.
    Wallentin, L.
    Held, C.
    Stewart, R.
    White, H. D.
    EUROPEAN HEART JOURNAL, 2011, 32 : 550 - 551
  • [10] Role of Lp-PLA2 in atherosclerosis
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (01) : 13 - 13
12345